FDAnews
www.fdanews.com/articles/97222-sinovac-commences-vaccination-in-study-of-pandemic-influenza-vaccine

Sinovac Commences Vaccination in Study of Pandemic Influenza Vaccine

August 15, 2007

China’s Sinovac Biotech announced that it has commenced vaccination of volunteers for the clinical research of H5N1 pandemic influenza vaccine, which is the continued research for its Phase I clinical trial of whole viron H5N1 vaccine and the beginning of its Phase I clinical trial of split H5N1 vaccine.

The Phase II clinical trials for the H5N1 vaccine were approved in April by the China State Food and Drug Administration, Sinovac said.
 
These clinical trials will be open-label and will assess the tolerance and safety of the vaccine, the company added.

The company said it anticipates that the Phase II trials will commence shortly and the preliminary results from these clinical trials for both vaccines will be available early next year.